Growing numbers of adolescents & young adults with ASD. Many young persons with ASD are at risk for reduced quality of life in adulthood. Across chronic illnesses and disabilities, providing care for ...
The new presentation, available on the PaxMedica website, outlines the company’s focused pipeline, including its leading investigational drug, PAX-101. With its approach to targeting the core symptoms ...
TARRYTOWN, New York, March 13, 2024 (GLOBE NEWSWIRE) -- via IBN – PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for neurological disorders, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results